| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $19 to $18.
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and raises the price target from $17 to $21.
Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and raises the price target from $16 to $19.
Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and raises the price target from $18 to $21.
Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid f...